An evaluation by the European Commission covers the legislation on medicines for special purposes, in particular medicines for children and medicines to treat rare diseases. The evaluation will assess to which extent the EU legislation is efficient and effective and considers whether it is fit for purpose in the light of developments in the area of pharmaceuticals. It will look in particular in the impact of the incentives introduced for research, development and marketing, for these specific medicines.

The public consultation is open until 11 January 2019. 

Go to HERE to view more